BioLineRx(BLRX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [18] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [19] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [20] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [20] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][20] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue for the company [12] - The company continues to support the development of motixafortide in pancreatic cancer, with a phase IIb clinical trial showing accelerated enrollment [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an annual incidence of approximately 18,500 patients in the U.S. and 13,500 in the EU [8] - The unmet need in glioblastoma treatment is significant, with current therapies showing limited advancements since 2005 [7] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma and other cancers, highlighting the enthusiasm from clinical investigators [38] - The company is well-positioned to drive innovation in challenging cancer types and is focused on maximizing the value of GLIX1 [56] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [16] - The company remains a lean organization following the shutdown of U.S. commercialization operations, concentrating on development [12] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [27][28] Question: Enthusiasm from principal investigators for GLIX1 trial - Investigators are highly enthusiastic about GLIX1 due to its novel mechanism and promising preclinical results [38] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway [44] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the study are recurrent or progressed GBM patients, having run out of standard care options [46] Question: Measurement of blood-brain barrier penetration in the study - While biopsies may be taken, the study is not designed to assess blood-brain barrier penetration as a primary measure [50] Question: Ayrmid's guidance on expected sales - Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [51]